Search results for "INHIBITORS"

showing 10 items of 2336 documents

Harnessing TH9 cells in cancer immunotherapy

2021

CD4 T cell effector subsets not only profoundly affect cancer progression, but recent evidence also underscores their critical contribution to the anticancer efficacy of immune checkpoint inhibitors. In 2012, the two seminal studies suggested the superior antimelanoma activity of TH9 cells over other T cell subsets upon adoptive T cell transfer. While these findings provided great impetus to investigate further the unique functions of TH9 cells and explore their relevance in cancer immunotherapy, the following questions still remain outstanding: are TH9 cell anticancer functions restricted to melanoma? What are the factors favouring TH9 cell effector functions? What is the contribution of T…

0301 basic medicinebusiness.industryEffectormedicine.medical_treatmentImmune checkpoint inhibitorsT cellMelanomaImmunologyCellCancerImmunotherapymedicine.disease3. Good health03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureCancer immunotherapy030220 oncology & carcinogenesisCancer researchImmunology and AllergyMedicinebusinessSeminars in Immunology
researchProduct

Statins in liver disease: not only prevention of cardiovascular events

2018

Statins are lipid-lowering agents and one of the most pre-scribed drugs worldwide. Their main mechanism of action –inhibition of the mevalonate pathway through an effect on hydroxy-methylglutaryl CoA reductase, thus affecting the synthesis of cholesterol in the liver – makes this class of drugs pivotal in primary and secondary prevention of cardio-vascular risk, as extensively demonstrated in large prospective, randomized controlled trials. Along the years, we learned that the lower the better, and LDL-cholesterol targets have been progressively reduced to values ≤70 mg/dL for secondary prevention or in the presence of diabetes.

0301 basic medicinecardiovascular riskmedicine.medical_specialtydrug safetyGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicineFatty livermedicineHumansHypolipidemic AgentsHepatologybusiness.industryFatty liverhydroxymethylglutaryl-CoA reductase inhibitorGastroenterologynon-alcoholic fatty liver diseaseHepatologymedicine.diseaseHydroxymethylglutaryl-CoA Reductase Inhibitors030104 developmental biologyCardiovascular DiseasesDisease Progressionlipids (amino acids peptides and proteins)030211 gastroenterology & hepatologyHydroxymethylglutaryl-CoA Reductase Inhibitorsbusiness
researchProduct

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

2020

AbstractCoronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct…

0301 basic medicinecoronavirusAnti-Inflammatory AgentsReview Article030204 cardiovascular system & hematologymedicine.disease_causelaw.inventioncovid190302 clinical medicineRandomized controlled triallawAntithromboticPandemicViralanticoagulationCoronavirusGlycosaminoglycansAnimals; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Fibrinolytic Agents; Glycosaminoglycans; Hemostasis; Humans; Inflammation; Pandemics; Platelet Aggregation Inhibitors; Pneumonia Viral; Thrombosiscoronavirus 2immunomodulatorHematologyHeparinThrombosisantithrombinCoronavirus Infectionsmedicine.drugmedicine.medical_specialtyPneumonia Viralcoronavirus disease 2019 thrombosis inflammation fibrinolytic therapy anticoagulation immunomodulator antithrombin thrombomodulinAntiviral Agents03 medical and health sciencescoronavirus disease 2019BetacoronavirusFibrinolytic AgentsmedicineAnimalsHumansthrombosis COVID-19 coronavirusDosingIntensive care medicinePandemicsthrombosisInflammationHemostasisbusiness.industrySARS-CoV-2AnticoagulantsCOVID-19ThrombosisPneumoniathrombomodulinmedicine.diseaseReview articleCOVID-19 Drug Treatment030104 developmental biologyinflammationfibrinolytic therapybusinessPlatelet Aggregation InhibitorsThrombosis and haemostasis
researchProduct

Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors

2020

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors are so called “incretin-based therapies” (IBTs) that represent innovative therapeutic approaches and are commonly used in clinical practice for the treatment of type 2 diabetes mellitus (T2DM). The cardiovascular outcome trials (CVOTs) have provided useful information that has helped to shape changes in clinical practice guidelines for the management of T2DM. At the same time, the mechanisms that may explain the nonglycemic and cardiovascular (CV) benefits of these medications are still being explored. A summary of the main findings from CVOTs performed to-date with particular emphasis on vari…

0301 basic medicineendocrine systemmedicine.medical_specialtyDipeptidyl Peptidase 4Endocrinology Diabetes and MetabolismIncretin030209 endocrinology & metabolismClass effectBody weightCardiovascular SystemIncretinsGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineType 2 diabetes mellitusmedicineAnimalsHumansIntensive care medicineGlucagon-like peptide 1 receptorDipeptidyl-Peptidase IV Inhibitorsbusiness.industryDPP-4 Inhibitorsdigestive oral and skin physiologyType 2 Diabetes MellitusCardiovascular riskDPP4- inhibitorClinical Practice030104 developmental biologyCardiovascular DiseasesGlucagon-like peptide 1 receptor agonistbusinessCardiovascular outcomesMetabolism
researchProduct

Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma Cells

2016

Recent evidence has reported that proton pump inhibitors (PPIs) can exert antineoplastic effects through the disruption of pH homeostasis by inhibiting vacuolar ATPase (H+-VATPase), a proton pump overexpressed in several tumor cells, but this aspect has not been deeply investigated in EAC yet. In the present study, the expression of H+-VATPase was assessed through the metaplasia-dysplasia-adenocarcinoma sequence in Barrett’s esophagus (BE) and the antineoplastic effects of PPIs and cellular mechanisms involved were evaluated in vitro. H+-VATPase expression was assessed by immunohistochemistry in paraffined-embedded samples or by immunofluorescence in cultured BE and EAC cell lines. Cells we…

0301 basic medicineesophageal adenocarcinomaIntracellular pHvacuolar ATPaseBiologymedicine.disease_causeBarrett's esophagus03 medical and health sciencesmedicineBarrett’s esophagusCytotoxic T cellPharmacology (medical)Original Researchreactive oxygen speciesPharmacologychemistry.chemical_classificationReactive oxygen specieslcsh:RM1-950AutophagyProton Pump InhibitorsIn vitrolcsh:Therapeutics. Pharmacology030104 developmental biologyBiochemistrychemistryCell cultureApoptosisCancer researchEsophageal adenocarcinomaproton pump inhibitorsReactive Oxygen SpeciesOxidative stressFrontiers in Pharmacology
researchProduct

Heat Shock Proteins in Alzheimer’s Disease: Role and Targeting

2018

Among diseases whose cure is still far from being discovered, Alzheimer’s disease (AD) has been recognized as a crucial medical and social problem. A major issue in AD research is represented by the complexity of involved biochemical pathways, including the nature of protein misfolding, which results in the production of toxic species. Considering the involvement of (mis)folding processes in AD aetiology, targeting molecular chaperones represents a promising therapeutic perspective. This review analyses the connection between AD and molecular chaperones, with particular attention toward the most important heat shock proteins (HSPs) as representative components of the human chaperome: Hsp60,…

0301 basic medicineheat shock proteinDiseaseReviewprotein TauHsp70lcsh:ChemistrychaperoneEnzyme Inhibitorslcsh:QH301-705.5SpectroscopybiologyGeneral MedicineHsp60Hsp90Computer Science Applicationsamyloid peptideModels AnimalHSP60Protein foldingAlzheimer’s diseaseheat shock proteins; chaperones; Alzheimer’s disease; amyloid peptide; protein Tau; Hsp60; Hsp70; Hsp90Tau proteintau ProteinsHsp90Computational biologyCatalysisInorganic ChemistryMitochondrial Proteins03 medical and health sciencesAlzheimer DiseaseHeat shock proteinAnimalsHumanschaperonesHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsPhysical and Theoretical ChemistryMolecular BiologyAmyloid beta-PeptidesSettore BIO/16 - Anatomia UmanaOrganic ChemistryChaperonin 60Settore CHIM/06 - Chimica OrganicaHsp70030104 developmental biologylcsh:Biology (General)lcsh:QD1-999heat shock proteinsbiology.protein
researchProduct

NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved.

2021

Due to the improved effectiveness and safety of combined antiretroviral therapy, human immunodeficiency virus (HIV) infection has become a manageable, chronic condition rather than a mortal disease. However, HIV patients are at increased risk of experiencing non-AIDS-defining illnesses, with liver-related injury standing out as one of the leading causes of death among these patients. In addition to more HIV-specific processes, such as antiretroviral drug-related toxicity and direct injury to the liver by the virus itself, its pathogenesis is related to conditions that are also common in the general population, such as alcoholic and non-alcoholic fatty liver disease, viral hepatitis, and age…

0301 basic medicinehepatotoxicityNevirapineEfavirenzQH301-705.5030106 microbiologyEtravirinecARTReviewBioinformaticsliver03 medical and health scienceschemistry.chemical_compoundLiver disease0302 clinical medicineDoravirinemedicineAnimalsHumans030212 general & internal medicineBiology (General)antiretroviral drugsbusiness.industryFatty livervirus diseasesHIVGeneral Medicinemedicine.diseasechemistryRilpivirineChronic DiseaseReverse Transcriptase InhibitorsDrug Therapy CombinationDILIChemical and Drug Induced Liver InjuryViral hepatitisbusinessmedicine.drugCells
researchProduct

New 3-Aryl-2-(2-Thienyl)acrylonitriles with High Activity against Hepatoma Cells

2021

New 2-(thien-2-yl)-acrylonitriles with putative kinase inhibitory activity were prepared and tested for their antineoplastic efficacy in hepatoma models. Four out of the 14 derivatives were shown to inhibit hepatoma cell proliferation at (sub-)micromolar concentrations with IC50 values below that of the clinically relevant multikinase inhibitor sorafenib, which served as a reference. Colony formation assays as well as primary in vivo examinations of hepatoma tumors grown on the chorioallantoic membrane of fertilized chicken eggs (CAM assay) confirmed the excellent antineoplastic efficacy of the new derivatives. Their mode of action included an induction of apoptotic capsase-3 activity, whil…

0301 basic medicinelcsh:Chemistry0302 clinical medicinelcsh:QH301-705.5SpectroscopyMolecular StructureKinaseChemistryLiver NeoplasmsGeneral MedicineHep G2 CellshepatomaComputer Science ApplicationsCAM assayMolecular Docking SimulationChorioallantoic membraneBiochemistry030220 oncology & carcinogenesistyrphostinTyrosine kinasemedicine.drugSorafenibCarcinoma HepatocellularthiopheneThiophenesCatalysisArticleInorganic ChemistryVEGFR inhibition03 medical and health sciencesStructure-Activity RelationshipIn vivomedicineHumansPhysical and Theoretical ChemistryMode of actionMolecular BiologyProtein Kinase InhibitorsCell ProliferationAcrylonitrileDose-Response Relationship DrugOrganic Chemistrymolecular dockingVascular Endothelial Growth Factor Receptor-2anticancer drugs030104 developmental biologylcsh:Biology (General)lcsh:QD1-999ApoptosisDocking (molecular)Drug Screening Assays AntitumorInternational Journal of Molecular Sciences
researchProduct

Nitration of Wheat Amylase Trypsin Inhibitors Increases Their Innate and Adaptive Immunostimulatory Potential

2018

Amylase trypsin inhibitors (ATI) can be found in all gluten containing cereals and are, therefore, ingredient of basic foods like bread or pasta. In the gut ATI can mediate innate immunity via activation of the Toll-like receptor 4 (TLR4) on immune cells residing in the lamina propria, promoting intestinal, as well as extra-intestinal, inflammation. Inflammatory conditions can induce formation of peroxynitrite (ONOO-) and, thereby, endogenous protein nitration in the body. Moreover, air pollutants like ozone (O3) and nitrogen dioxide (NO2) can cause exogenous protein nitration in the environment. Both reaction pathways may lead to the nitration of ATI. To investigate if and how nitration mo…

0301 basic medicinelcsh:Immunologic diseases. AllergyCell SurvivalT cellnon-celiac wheat sensitivityImmunologyInflammationAdaptive ImmunityImmunophenotyping03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemprotein nitrationT-Lymphocyte SubsetsNitrationCell Line TumorwheatmedicineImmunology and AllergyHumansamylase trypsin inhibitorsTriticumPlant ProteinsOriginal ResearchInnate immune systemMacrophagesfood and beveragesDendritic CellsTetranitromethaneallergyImmunity InnateToll-Like Receptor 4030104 developmental biologymedicine.anatomical_structurechemistryBiochemistryAmylasesTLR4Cytokinesmedicine.symptomlcsh:RC581-607Trypsin InhibitorsPeroxynitriteBiomarkers030215 immunologyFrontiers in immunology
researchProduct

Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives

2017

urpose Everolimus has been shown to be effective for advanced pancreatic neuroendocrine tumours (pNETs), but its positioning in the therapeutic algorithm for pNETs is matter of debate. Methods With the aim to shed light on this point, we performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies, and the recommendations of international guidelines. In addition, we performed an extensive search on the Clinical Trial Registries databases worldwide, to gather information on the ongoing clinical trials related to this specific topic. Results We identified eight retrospective published studies, two prospective published studies…

0301 basic medicinemTOR inhibitorsCancer Researchmedicine.medical_specialtyPathologymTOR inhibitorEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Oncology; Cancer ResearchTherapeutic algorithmEverolimus; mTOR inhibitors; neuroendocrine tumours; therapy; antineoplastic agents; everolimus; humans; neuroendocrine tumours; pancreatic neoplasms; oncology; cancer researchEndocrine SyndromeNeuroendocrine tumorsAntineoplastic Agent03 medical and health sciences0302 clinical medicineFirst line therapyNeuroendocrine tumourantineoplastic agentsmedicinehumansIntensive care medicinetherapyEverolimusbusiness.industryPancreatic Neoplasmpancreatic neoplasmsGeneral Medicineeverolimusmedicine.diseaseDiscovery and development of mTOR inhibitorsClinical trialEverolimuNeuroendocrine Tumors030104 developmental biologyOncology030220 oncology & carcinogenesisneuroendocrine tumoursNeuroendocrine TumorbusinessEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic NeoplasmsHumanmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct